GH Research PLC will participate in the 64th American College of Neuropsychopharmacology annual meeting from January 12-15, 2026, presenting results on its GH001-TRD-201 clinical trial. The presentation will cover improvements in illness severity, anxiety symptoms, and quality of life for patients with treatment-resistant depression.